Literature DB >> 16675787

Inhaled insulin.

Emma Morton-Eggleston, Eugene J Barrett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16675787      PMCID： PMC1458606          DOI： 10.1136/bmj.332.7549.1043

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs.

Authors:  Dale S Edgerton; Doss W Neal; Melanie Scott; Larry Bowen; Warren Wilson; Charles H Hobbs; Chet Leach; Shantha Sivakumaran; Thomas R Strack; Alan D Cherrington
Journal:  Diabetes       Date:  2005-04       Impact factor: 9.461

2.  Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.

Authors:  S Garg; J Rosenstock; B L Silverman; B Sun; C S Konkoy; A de la Peña; D B Muchmore
Journal:  Diabetologia       Date:  2006-02-28       Impact factor: 10.122

3.  Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial.

Authors:  R A Gerber; J C Cappelleri; I A Kourides; R A Gelfand
Journal:  Diabetes Care       Date:  2001-09       Impact factor: 19.112

4.  Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.

Authors:  Teresa Quattrin; André Bélanger; Nancy J V Bohannon; Sherwyn L Schwartz
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

5.  Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen.

Authors:  Joseph C Cappelleri; William T Cefalu; Julio Rosenstock; Ione A Kourides; Robert A Gerber
Journal:  Clin Ther       Date:  2002-04       Impact factor: 3.393

6.  Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

Authors:  W T Cefalu; J S Skyler; I A Kourides; W H Landschulz; C C Balagtas; S Cheng; R A Gelfand
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

7.  Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.

Authors:  S Edwin Fineberg; Tom Kawabata; Deborah Finco-Kent; Cameron Liu; Alan Krasner
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

8.  Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy.

Authors:  John G Teeter; Richard J Riese
Journal:  Am J Respir Crit Care Med       Date:  2006-03-23       Impact factor: 21.405

9.  Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.

Authors:  Stuart R Weiss; Shu-Lin Cheng; Ione A Kourides; Robert A Gelfand; William H Landschulz
Journal:  Arch Intern Med       Date:  2003-10-27

10.  Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.

Authors:  Julio Rosenstock; Joseph C Cappelleri; Björn Bolinder; Robert A Gerber
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112
View more
  2 in total

1.  Inhaled insulin: concerns remain.

Authors:  Niamh M Martin; Karim Meeran
Journal:  BMJ       Date:  2006-05-27

2.  Inhaled insulin: evidence based or industry driven medicine?

Authors:  H Alberti
Journal:  BMJ       Date:  2006-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.